1P9U image
Deposition Date 2003-05-12
Release Date 2003-05-20
Last Version Date 2024-10-30
Entry Detail
PDB ID:
1P9U
Title:
Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of anti-SARS Drugs
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.37 Å
R-Value Free:
0.23
R-Value Work:
0.19
R-Value Observed:
0.2
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:putative coronavirus nsp2 (3CL-PRO)
Chain IDs:A, B, C, D, E, F
Chain Length:302
Number of Molecules:6
Biological Source:Transmissible gastroenteritis virus
Polymer Type:polypeptide(L)
Molecule:PHQ-VNSTLQ-CHLOROMETHYLKETONE INHIBITOR
Chain IDs:G, H
Chain Length:8
Number of Molecules:2
Biological Source:
Peptide-like Molecules
PRD_000457
Primary Citation
Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of anti-SARS Drugs
Science 300 1763 1767 (2003)
PMID: 12746549 DOI: 10.1126/science.1085658

Abstact

A novel coronavirus has been identified as the causative agent of severe acute respiratory syndrome (SARS). The viral main proteinase (Mpro, also called 3CLpro), which controls the activities of the coronavirus replication complex, is an attractive target for therapy. We determined crystal structures for human coronavirus (strain 229E) Mpro and for an inhibitor complex of porcine coronavirus [transmissible gastroenteritis virus (TGEV)] Mpro, and we constructed a homology model for SARS coronavirus (SARS-CoV) Mpro. The structures reveal a remarkable degree of conservation of the substrate-binding sites, which is further supported by recombinant SARS-CoV Mpro-mediated cleavage of a TGEV Mpro substrate. Molecular modeling suggests that available rhinovirus 3Cpro inhibitors may be modified to make them useful for treating SARS.

Legend

Protein

Chemical

Disease

Primary Citation of related structures